Brainsway ( (BRSYF) ) has released its Q1 earnings. Here is a breakdown of the information Brainsway presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The company operates primarily in the healthcare sector, focusing on innovative solutions for mental health conditions.
In its first quarter of 2025, BrainsWay reported record quarterly sales of $11.5 million, marking a 27% increase compared to the same period in 2024. The company also achieved significant growth in operating profit and Adjusted EBITDA, reflecting strong demand for its Deep TMS systems.
Key financial highlights include a 519% increase in operating profit to $0.6 million and an 81% rise in Adjusted EBITDA to $1.3 million. The company shipped a net total of 81 Deep TMS systems, a 42% increase from the previous year, and maintained a gross margin of 75%. Additionally, BrainsWay reported a net profit increase of 897% to $1.1 million.
Looking ahead, BrainsWay reiterates its full-year 2025 financial guidance, projecting revenues between $49 million and $51 million, with an operating profit margin of 3% to 4% and Adjusted EBITDA of 11% to 12%. The company continues to expand its market presence globally, with ongoing clinical trials and new product developments expected to drive future growth.